diabetic nephropathy

JMP has reiterated its Market Outperform rating on Retrophin Inc (NASDAQ: RTRX). The recently held expert call suggests recent DUET data for sparsentan are impressive, but JMP would like over a year's worth of data in order to see the full impact on disease progression. JMP hosted the call with...